Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hairy Cell Leukemia: early-phase trial registry
8 of 16 indexed Hairy Cell Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 8 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Hairy Cell Leukemia: 16 US clinical trials tracked, 8 recruiting.
Hairy Cell Leukemia is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 9 of these trials.
Enrollment posture brief
Registry condition hairy-cell-leukemia
OPEN 8 | RECR 50% | LATE 0 | EARLY 16 | RANK #1060 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Hairy Cell Leukemia lists 8 open slots (50% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hairy Cell Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hairy Cell Leukemia is recruiting above its size-band peers.
8 of 16 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hairy Cell Leukemia research.
National Cancer Institute (NCI) accounts for 9 of 16 trials (56.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Hairy Cell Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 56 among the 16 trials that report a genuine target (sentinel values excluded). 13 of those (81.3%) plan for fewer than 100 participants.
-
Hairy Cell Leukemia research is mostly interventional.
16 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
M.D. Anderson Cancer Center
NCT00412594
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
NCT06340737
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
NCT06561360
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
National Cancer Institute (NCI)
NCT06965114
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical
NCT04775745
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
National Cancer Institute (NCI)
NCT04324112
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
National Cancer Institute (NCI)
NCT04322383
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
National Cancer Institute (NCI)
NCT04815356
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
National Cancer Institute (NCI)
NCT00923013
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Cancer Institute (NCI)
NCT01059786
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
National Cancer Institute (NCI)
NCT01841723
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
NCT03410875
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Scripps Health
NCT05388123
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
National Cancer Institute (NCI)
NCT03805932
A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia
National Cancer Institute (NCI)
NCT00001567
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
NCT01711632
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Hairy Cell Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hairy Cell Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hairy Cell Leukemia page
16 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Hairy Cell Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Hairy Cell Leukemia trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hairy Cell Leukemia condition card totals 16 registered trials; most-linked intervention Cladribine; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.